Anifrolumab in the Real-World Management of Systemic Lupus Erythematosus

Anifrolumab has been described as a game-changer for people with systemic lupus erythematosus (SLE) and first real-world experience of the drug suggests a quarter of patients could go into remission within months of being prescribed it. The first real-world data for the drug, which was first cleared by US regulators in March, is being described as ‘very encouraging’ and already patients, clinicians and health systems are asking what this means for future treatment pathways, budgets and longer-term care.

Systemic lupus erythematosus (SLE)

Systemic lupus erythematosus (SLE) affects more than 5 million people worldwide and is characterized by loss of self-tolerance and the production of autoreactive antibodies that cause inflammation of various organs. Current treatment strategies for SLE include broad immunosuppression and high-dose corticosteroids, which can induce complete remission of symptoms. However, such therapies carry a risk of irreversible organ damage, a serious and often life-threatening consequence of SLE. The recent US Food and Drug Administration approval of anifrolumab provides patients and their clinicians hope for more effective and safer treatment of SLE, the first mechanism-targeted approach developed to-date that blocks type I interferons (IFNs). Up to 80% of adult patients with SLE have increased levels of type I IFNs.

Recent real-world evidence (RWE)

In order to get a first glance into the effectiveness of belimumumab in real world settings, data from a multicenter clinical cohort of SLE patients was analyzed. Patients (n=104) from different centers in different countries that received belimumumab were included in the study. Early effectiveness was documented in 26% of the patients that achieved the Definition of Remission in SLE (DORIS) by six months of belimumumab treatment. Importantly, these patients had higher disease activity, more organ damage and were on more prior medications than patients that were included in clinical trials of belimumumab.

Why It Matters

Lupus affects millions of people worldwide and typically requires chronic, often disabling treatment. Because the disease can wax and wane in individual patients and symptomatically vary between them, treatments that can reliably suppress disease activity and even induce remission are a significant unmet clinical need. Anifrolumab is an experimental treatment for lupus that targets the type I interferon (IFN) pathway, which is thought to contribute to the disease in many patients with lupus.

Current knowledge of hepatitis C has largely been developed through clinical trials, which may not reflect real-world patient populations. In contrast, data from observational settings such as primary care offer a unique perspective on typical patient populations.

• Trial-to-Practice Translation: It translates trial-era promise into everyday practice, where patients have comorbidities, varying adherence, and heterogeneous prior treatment histories. In the SAPPHIRE study, the median SLEDAI-2K score (a measure of disease activity) dropped from 10 at baseline to just 4 at six months, demonstrating significant clinical improvement even in those who did not reach full remission.
• Steroid Sparing: The pace and durability of response affect downstream care. Achieving remission or low disease activity can reduce reliance on corticosteroids. This is critical because long-term steroid use carries risks like infection, bone thinning, diabetes, and cardiovascular disease. Real-world data showed that the median daily prednisone dose decreased from 10 mg to 5 mg within six months, with 60.3% of patients successfully reducing their steroid load.
• Targeting the “Interferon Signature”: Unlike previous therapies, anifrolumab specifically addresses the interferon signature that is prevalent in patients with severe skin and joint involvement. By blocking the IFNAR1 receptor, the drug prevents the downstream signaling of multiple type I interferons, effectively dampening the immune system’s overactive response.
• Resource Allocation: The arrival of newer targeted therapies reshapes resource allocation. Biologics are costly and often require prior authorization and infusion infrastructure. Payers and health systems must now assess how to integrate anifrolumab into formularies alongside established options like belimumab, especially for patients with refractory disease.

Who It Affects

Anifrolumab is likely to provide benefit for the most immediately relevant group of patients with moderate-to-severe systemic lupus who have an active disease state and are on current standard therapy and/or other immunosuppressive medications. For some patients, anifrolumab may be considered as an alternative for use when there has been inadequate response to conventional immunosuppressive agents and/or other biologic therapies, including belimumab. In the real-world study cohort, 38.5% of patients had been treated with belimumab at the time of enrolment. As such, anifrolumab is a useful secondary therapy option for these individuals.

• The Refractory Patient: People with skin-predominant and joint-predominant disease, where interferon-driven inflammation is most evident, are considered primary beneficiaries. The RWE showed that 72.1% of patients with joint involvement and 66.7% of those with skin involvement achieved a clinical response (improvement of ≥4 points in SLEDAI-2K) by month six.
• Clinicians: Rheumatologists, nephrologists, and dermatologists must incorporate discussions about expected benefits and practical logistics. The 6-month remission marker provides a definitive timepoint for assessing response and deciding whether to switch therapies or adjust the treatment baseline.
• Health Systems and Payers: The cost of biologic therapy and the infrastructure for administration (such as monthly intravenous infusions) influence treatment access. Insurers may require step therapy, demanding that patients fail traditional immunosuppressants before approving anifrolumab.
• Advocacy Groups: Organizations like theLupus Foundation of America watch these real-world outcomes closely to advocate for policies that prioritize patient need over short-term cost containment.

What Changes

This review will outline how the introduction of anifrolumab will alter our approach to the management of severe skin disease.

1. Earlier Targeted Intervention: Care pathways may shift toward earlier introduction of mechanism-targeted biologics for selected patients, moving away from prolonged “waiting periods” on steroids.
2. Measurable Benchmarks: Clinicians gain an additional targeted option with measurable early remission potential (26% at 6 months) to guide treatment planning.
3. Process Expansion: Health systems need to expand processes for prior authorization, infusion logistics, and post-initiation monitoring to manage safety signals, such as the risk of Herpes Zoster (shingles).
4. Low Disease Activity Goals: Beyond remission, the concept of Low Disease Activity (LDA) has gained traction. In real-world data, 45.2% of patients reached LDA by six months, providing a broader, achievable target for clinical success.

Clinical Decision-Making and Patient Experience

The decision to use anifrolumab would be individualised. The doctor would consider the patient’s clinical characteristics or course of disease as well as their circumstances. Anifrolumab has high efficacy for cutaneous lupus (skin disease) which can be very disfiguring and affects a patient’s mental health.

Trade-offs between different options must be transparent. Anifrolumab (ratibuprotna) is likely to reduce the frequency of flares and the amount of steroid medication that patients need, but it increases the risk of infections with certain viruses including shingles. From the patient’s point of view, early remission means more than a reduction in the frequency of disease flares. Early remission means early return of function and this means:

• Reduced Burden: Fewer sudden clinic visits for flare management and a reduction in the moon face or weight gain side effects associated with high-dose steroids.
• Productivity: An improved ability to maintain employment or attend school, which is often interrupted by the extreme fatigue and joint pain of active lupus.
• Logistical Navigation: Patients must, however, manage the practical burdens of monthly infusions and the rigorous monitoring of bloodwork required to ensure the therapy is not causing unintended harm to the liver or kidneys.

Safety, Monitoring, and Trade-offs

Similar to other biologic agents, safety measures must be considered and adhered to. Before initiating anifrolumab, patients should be screened for latent Mycobacterium tuberculosis infection and be up-to-date on all vaccinations, including Shingrix for prevention of herpes zoster. Anifrolumab is an immune-modulating agent that can result in an infusion reaction, which occurred in less than 10% of patients.

When deciding whether or not to continue therapy beyond 6 months, a benefit-risk assessment must be considered. Patients and providers will want to see continued meaningful clinical improvement as measured by an SLEDAI-2K score as well as the ability to taper steroids. For the majority of patients with SLE, the cost of continued therapy, coupled with the risk of infection will outweigh the benefits of continuing anifrolumab, given the RWD demonstrating that greater than 80% of patients who started anifrolumab are still on the medication at 6 months.

System-Level Implications

Anifrolumab will require a thoughtful approach by providers and clinical settings to incorporate this new medication into workflow and patient space. Many infusion centers are currently at full capacity, serving patients on rheumatoid arthritis and cancer medications. Each treatment will take 30 minutes and are given every 4 weeks. Providers will need to spend time counseling patients and their families as to the time-to-effect of this medication. Most patients with lupus do not experience rapid remission.

As anifrolumab is an emerging treatment for SLE it is predicted to be very costly. This makes equity considerations particularly relevant because this costly treatment is unlikely to be accessible to many women with SLE, particularly women of color who already face numerous barriers to accessing specialty care due to a variety of inequitable structural factors. Leaving access to a promising emerging treatment for patients with SLE to depend on their ability to successfully navigate the insurance system is precisely the type of emerging innovation gap between socioeconomic groups that we should strive to avoid. Policy makers and healthsystems therefore need to develop effective financial navigation strategies as well as streamlined approval pathways in order to ensure access to anifrolumab for patients with SLE without creating further health inequities.

What Comes Next

In the short-term clinicians will be able to use the 6 month remission and LDA (45%) thresholds (27% for the 6 month remission threshold). We are also starting to see the first of the new trials open to recruitment including the SLE-ARTEMIS trial (NCT06673043) which will investigate the long-term safety and efficacy of anifrolumab in a more general clinical population.

Medium-term goals include:

• Durability of Response: Determining if patients who reach remission at six months can sustain that state for years.
• Organ-Specific Outcomes: Gathering more data on anifrolumab’s role in treating lupus nephritis (kidney inflammation), a common and severe complication where interferon signaling is also highly relevant.
• Comparative Effectiveness: Using registries to compare anifrolumab directly with belimumab or rituximab to determine the optimal sequencing of therapies.

On a more optimistic note, we like to think of SLE in the long-term, imagining what it means to patients to achieve a drug-free remission (DORIS). Can patients be on anifrolumab and go into DORIS remission and have the medication tapered down or stopped. These are long-term questions that will require many years of data collection from all around the world to answer.

Bottom Line

In this small open label trial, about one in four of the patients went into remission by six months. This is huge for lupus patients and their clinicians, as it confirms the mechanism-based promise of interferon blockade has real world consequences and translates into clinical improvement that is steroid sparing.